Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal

 
• By John Davis
  
Teamwork
Novo Nordisk has licensed a small-molecule program • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business